Rowland Carmichael Advisors’s Charles River Laboratories CRL Stock Holding History

Rowland Carmichael Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$203K	Buy	+813	New	+$194K	0.06%	292

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Rowland Carmichael Advisors's CRL Position: Q4 2020 in Review

Rowland Carmichael Advisors opened a new position in Charles River Laboratories (CRL) in Q4 2020: 813 shares worth $203K. The stake represents 0.06% of the portfolio and ranks #292 among its holdings.

538 funds tracked by Wall St. Rank hold CRL as of Q4 2020.

Rowland Carmichael Advisors held 813 shares of Charles River Laboratories worth $203K as of Q4 2020.
Charles River Laboratories was a new Rowland Carmichael Advisors position in Q4 2020.
Charles River Laboratories made up 0.06% of Rowland Carmichael Advisors's portfolio in Q4 2020, its #292 holding.
538 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2020.

Based on Rowland Carmichael Advisors's 13F filing for Q4 2020, filed 15 Jan 2021.